Angiogenesis — the sprouting of new blood vessels — is central to tissue repair, wound healing, and metabolism research. When testing a peptide for pro-angiogenic activity, researchers use standardized in vitro and in vivo models that measure tube formation, vessel density, or vascular permeability. This guide covers the most common assays and their strengths and limitations.
The tube formation assay is the workhorse of early-stage angiogenesis screening. Endothelial cells (typically human umbilical vein endothelial cells, HUVECs) are seeded on a matrix scaffold (Matrigel or Collagen I) and treated with the test peptide. Within hours, endothelial cells self-organize into tubule-like structures. Angiogenic factors increase tube formation; inhibitors reduce it.
Readout: Number of tubes, branch points, or total tube length per microscopic field, typically quantified by image analysis software.
Pros: Quick (24–48 hours), repeatable, uses human cells, inexpensive, good for high-throughput screening.
Cons: In vitro only — does not capture the complex tissue microenvironment or systemic factors. Matrigel itself is a crude extract with batch-to-batch variability.
Endothelial cells are seeded in the upper chamber of a permeable insert, and the test peptide (or a chemoattractant) is placed in the lower chamber. Cells migrate downward through the pores. After incubation (typically 4–24 hours), cells on the underside of the membrane are counted (via staining or fluorescence).
Readout: Number of migrated cells per field.
Pros: Measures endothelial cell motility, a key component of angiogenesis. Simple, reproducible, and quantitative.
Cons: In vitro only; does not measure actual tube formation or vessel branching.
The CAM is a highly vascularized membrane in avian eggs that is easily accessible and transparent. A test compound is applied to the CAM surface (often embedded in a sterile disc or pellet). After 48–72 hours, new blood vessels grow toward the stimulus. Vessel density and branching are quantified via microscopy or image analysis.
Pros: In vivo angiogenic response; transparent observation; avoids ethical concerns of live mammalian surgery; good for qualitative screening.
Cons: Avian physiology differs from mammalian; limited quantitative precision; regulatory acceptance is lower than mammalian models.
A bolus of growth-factor-reduced Matrigel mixed with the test peptide is injected subcutaneously into a mouse. The Matrigel polymerizes into a plug. After 7–14 days, the plug is excised, sectioned, and stained for endothelial markers (CD31, VEGFR2). Vessel infiltration and density are quantified.
Pros: Mammalian in vivo model; well-established and reproducible; plug can be extracted and analyzed histologically for vessel morphology and immune infiltration.
Cons: Matrigel itself has intrinsic angiogenic activity, making it hard to measure the peptide's contribution; Matrigel batches vary; requires animal housing and euthanasia.
A tiny pellet containing the test peptide is implanted in a pocket created in the mouse cornea (the avascular dome of the eye). Over 5–7 days, new blood vessels sprout from the limbal blood vessels toward the pellet. Vessel growth (measured in millimeters from the limbus) and vessel density are quantified via slit-lamp microscopy or image analysis.
Pros: Highly sensitive for angiogenic potency; avascular baseline makes small increases in vessel formation easy to detect; clinically relevant (directly measures neo-vascularization).
Cons: Requires surgical skill; cornea is immune-privileged (unusual microenvironment); not ideal for screening large numbers of compounds.